NAVIFY® Tumor Board: improving cancer care
With data integration provided by Accenture, Roche's NAVIFY® Tumor Board is fundamentally changing the way tumor board meetings are organized and conducted.
Cancer care is complex and time-sensitive, and oncologists and other healthcare specialists need the most accurate, up-to-date patient information to do their jobs. For these professionals to arrive at the best treatment decisions, hospitals need to integrate many strands of patient data from different sources. Many important decisions for cancer patients are made at tumor board meetings in which experts from different disciplines review and discuss individual cases and treatment options.
Preparing for tumor board meetings is often labor-intensive and time-consuming, requiring patient data to be collected from various systems and consolidated manually. There is also no easy way to track whether and how the agreed upon decisions are put into effect.
Roche’s vision is to drive personalized healthcare through digital solutions. NAVIFY Decision Support portfolio is designed to provide care teams with comprehensive data and powerful solutions that allow for more time to be spent on their patients. NAVIFY Tumor Board empowers multidisciplinary cancer care teams to be both more efficient and more effective in determining next steps for cancer cases.
Today, hospitals typically use a broad array of IT systems to store and work with electronic data around the patient — from electronic medical records (EMR), laboratory and radiology systems, and picture archiving communication systems (PACS) to discipline-specific systems. During a tumor board meeting, a cancer care team today needs to access data from a number of these systems individually.
NAVIFY Tumor Board consolidates data across these systems and presents it in a tailor-made user interface. Roche uses Accenture, a global leader in the field of life sciences and health IT, to provide sophisticated data integration services to NAVIFY Tumor Board customers.
Accenture provides digital data integration services for NAVIFY Tumor Board through a proprietary data integration platform that is based on MuleSoft technology and leverages the public cloud as its foundation.
In doing so, Accenture contributes to the overall objective of NAVIFY Tumor Board — to improve the way cancer patients are cared for.
Specifically, Accenture is:
Setting up the digital data integration solution for each hospital that becomes a customer of NAVIFY Tumor Board.
Providing support for the daily data communication between each hospital and NAVIFY Tumor Board.
Enriching data integration capabilities over time by leveraging advanced technologies such as artificial intelligence.
The digital data integration platform automatically pulls a broad set of patient data into NAVIFY Tumor Board, including patient histories and care plans, medication information, lab results, pathology and radiology reports, genomic sequencing information, procedures and more.
The digital data integration platform securely validates and streamlines patient data and propagates it to NAVIFY Tumor Board so that all relevant patient data is available in one place, following a consistent data model. It uses a specifically developed data integration architecture that can take in data via a widely used format referred to as “Health Level 7” (HL7) or via individual solutions when HL7 is not an option.
Accenture helps Roche aggregate the relevant patient data stored across multiple systems at each hospital. With Accenture's digital data integration services, Roche can develop and scale additional clinical decision support solutions to improved patient outcomes using their deep experience in oncology across R&D, diagnostics and therapeutics.
With digital data integration provided by Accenture, NAVIFY Tumor Board is fundamentally changing the way tumor board meetings are organized and conducted.
These benefits greatly contribute to helping healthcare professionals make the best decisions for cancer patients swiftly, along tight schedules where the quality and speed of decision-making can be critical.
The benefits include:
Less time required to prepare for tumor board meetings.
Easier access to data across multiple systems.
More time for specialists to discuss their patients versus manage the technicalities of meeting operations.
Reduced manual entry.
Significant improvements in overall workflow efficiency.
Better continuity and comparability across tumor board meetings.
The University of Missouri Hospital (MU) was seeking a way to manage the complex processing of records from multiple systems automatically — as many as 30,000 clinical messages about patients per day.
They selected NAVIFY Tumor Board. Working with Roche, Accenture collaborated with MU to automate data integration via the platform for four tumor boards: hematology/pathology; breast; ear, nose and throat; and multidisciplinary. Since go-live in November 2018, the digital data integration platform feeds the patient data required for respective tumor board meetings into NAVIFY Tumor Board on an ongoing basis.
The cancer care teams of MU report tumor board processes are more streamlined. They also highlight time savings in preparing patient cases for review and the more comprehensive view of patient data. And they praise automated data integration for making an important contribution to how they’re able to help their cancer patients.
million data communication messages processed in the first 9 months at MU
thousand relevant messages sent to NAVIFY Tumor Board
cancer patients attended to on the back of automated date integration